News Quantified

MNOV – medicinova, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

MediciNova (NASDAQ:MNOV) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $9.00 price target on the stock.

MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN-166 (ibudilast) in ALS patients [Yahoo! Finance]

MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN-166 (ibudilast) in ALS patients

MediciNova (NASDAQ:MNOV) was upgraded by analysts at Lucid Cap Mkts to a "strong-buy" rating.

2026 New Year’s Greetings from the CEO

1.0%

BEAT

0.8%

IN-LINE

Form 4 MEDICINOVA INC For: Jan 16 Filed by: Matsuda Kazuko

Form 4 MEDICINOVA INC For: Jan 16 Filed by: IWAKI YUICHI

Form 424B5 MEDICINOVA INC

Form 8-K MEDICINOVA INC For: Dec 29

Form EFFECT MEDICINOVA INC

Top News Gainers

4/8 MediciNova Announces Plans to Initiate a Clinical Trial of MN-166 (ibudilast) for COVID-19 Acute Respiratory Distress Syndrome (ARDS) 37.8%

3/12 Form 4 MEDICINOVA INC For: Mar 12 Filed by: IWAKI YUICHI 30.2%

4/9 MediciNova, Inc. (NASDAQ: MNOV) had its "buy" rating re-affirmed by analysts at B. Riley. They now have a $11.00 price target on the stock. 26.1%

7/11 MediciNova Announces Phase 3 Clinical Trial Plan for MN-166 (ibudilast) in Progressive MS 14.5%

3/16 Form 4/A MEDICINOVA INC For: Mar 13 Filed by: Matsuda Kazuko 7.8%

4/23 Q1/2020 3/31/2020 EPS -0.060 ZacksConsensus -0.080 ActVsEst 0.020 - Beat 4.6%

8/23 Form 424B5 MEDICINOVA INC 3.8%

8/20 MediciNova: Leading The Pack In An MS Subtype [Seeking Alpha] 3.5%

5/7 MediciNova Participated in the RECEDE Phase 3 Degenerative Cervical Myelopathy Trial Kick-off Meeting, DCM Symposium and the Official Launch of Myelopathy.org in London, United Kingdom 3.1%

1/27 MediciNova Receives Notice of Intention to Grant for New Patent Covering MN-001 for the Treatment of Idiopathic Pulmonary Fibrosis in Europe 2.8%

Top News Decliners

10/24 Q3/2019 9/30/2019 EPS -0.050 ZacksConsensus -0.150 ActVsEst 0.100 - Beat -12.8%

4/13 Form 4 MEDICINOVA INC For: Jul 13 Filed by: IWAKI YUICHI -6.7%

8/23 Form EFFECT MEDICINOVA INC -6.7%

3/9 MediciNova Announces Plans to Develop MN-166 (ibudilast) for Severe Pneumonia and Acute Respiratory Distress Syndrome (ARDS) -5.3%

2/17 MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Japan -5.2%

7/24 MediciNova Appoints Kazuko Matsuda to its Board of Directors -4.9%

4/20 MediciNova Receives Notice of Allowance for Second Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma -4.8%

8/9 Form S-3 MEDICINOVA INC -4.7%

4/16 Form 8-K MEDICINOVA INC For: Apr 15 -4.4%

9/30 MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of Idiopathic Pulmonary Fibrosis in China -3.8%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day